Early piperacillin/tazobactam administration and sepsis-induced cardiomyopathy in emergency department patients: An observational study and exploratory prediction model

Abstract: Background: Sepsis-induced cardiomyopathy (SICM), a significant cardiovascular complication of sepsis, necessitates prompt and effective management. While timely antimicrobial treatment forms the bedrock of early sepsis management, the relationship between the timing of piperacillin/tazobactam administration and the development of SICM remains incompletely characterized. Objectives: The primary objective of this study was to investigate the association between early piperacillin/tazobactam administration and SICM incidence and short-term outcomes. A secondary objective was to identify factors associated with SICM and to develop an exploratory model for its prediction. Methods: This single-center, retrospective observational study included 149 adults with sepsis admitted between January 2023 and January 2026. Patients were categorized into two groups: Early treatment (≤1 h; n=68) or delayed treatment (>1 h; n=81). SICM was assessed using echocardiographic criteria. Clinical outcomes were compared using univariate and multivariable logistic regression. Internal validation was performed using 1,000 bootstrap resamples. Results: SICM occurred in 15/68 (22.06%) early-treatment patients and 33/81 (40.74%) delayed-treatment patients (P=0.014). Twenty-eight-day mortality was 14.71% versus 29.63% (P=0.029) and ICU and total hospital stays were shorter in the early-treatment group (both P<0.001). Delayed treatment (OR=2.354, 95% CI 1.044–5.310), SOFA ≥8 (OR=2.762, 95% CI 1.215–6.279), NT-proBNP ≥1500 pg/mL (OR=3.019, 95% CI 1.320–6.906) and each 0.1-ng/mL elevation in cTnI (OR=1.208, 95% CI 1.037–1.408) were independently linked to SICM. The model AUC was 0.842 (95% CI 0.776–0.908); Hosmer–Lemeshow P=0.409. Conclusion: Early administration of piperacillin/tazobactam was associated with lower SICM incidence and improved short-term outcomes. However, because this study is retrospective, a causal relationship cannot be definitively established. Furthermore, the exploratory prediction model developed warrants external validation to confirm its generalizability and accuracy.

Authors

Institutions

Publication Details

Journal
Pakistan Journal of Pharmaceutical Sciences
Published
2026-11-09
DOI
https://doi.org/10.36721/pjps/2026.40.16885.1
Primary Topic
Sepsis Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Early piperacillin/tazobactam administration and sepsis-induced cardiomyopathy in emergency department patients: An observational study and exploratory prediction model

Lu Liu
Pakistan Journal of Pharmaceutical Sciences
Sepsis Diagnosis and Treatment
article

Early piperacillin/tazobactam administration and sepsis-induced cardiomyopathy in emergency department patients: An observational study and exploratory prediction model

Lu Liu
article en

Abstract

Abstract: Background: Sepsis-induced cardiomyopathy (SICM), a significant cardiovascular complication of sepsis, necessitates prompt and effective management. While timely antimicrobial treatment forms the bedrock of early sepsis management, the relationship between the timing of piperacillin/tazobactam administration and the development of SICM remains incompletely characterized. Objectives: The primary objective of this study was to investigate the association between early piperacillin/tazobactam administration and SICM incidence and short-term outcomes. A secondary objective was to identify factors associated with SICM and to develop an exploratory model for its prediction. Methods: This single-center, retrospective observational study included 149 adults with sepsis admitted between January 2023 and January 2026. Patients were categorized into two groups: Early treatment (≤1 h; n=68) or delayed treatment (>1 h; n=81). SICM was assessed using echocardiographic criteria. Clinical outcomes were compared using univariate and multivariable logistic regression. Internal validation was performed using 1,000 bootstrap resamples. Results: SICM occurred in 15/68 (22.06%) early-treatment patients and 33/81 (40.74%) delayed-treatment patients (P=0.014). Twenty-eight-day mortality was 14.71% versus 29.63% (P=0.029) and ICU and total hospital stays were shorter in the early-treatment group (both P<0.001). Delayed treatment (OR=2.354, 95% CI 1.044–5.310), SOFA ≥8 (OR=2.762, 95% CI 1.215–6.279), NT-proBNP ≥1500 pg/mL (OR=3.019, 95% CI 1.320–6.906) and each 0.1-ng/mL elevation in cTnI (OR=1.208, 95% CI 1.037–1.408) were independently linked to SICM. The model AUC was 0.842 (95% CI 0.776–0.908); Hosmer–Lemeshow P=0.409. Conclusion: Early administration of piperacillin/tazobactam was associated with lower SICM incidence and improved short-term outcomes. However, because this study is retrospective, a causal relationship cannot be definitively established. Furthermore, the exploratory prediction model developed warrants external validation to confirm its generalizability and accuracy.

Pakistan Journal of Pharmaceutical Sciences
First Affiliated Hospital of Soochow University (CN)
Sepsis Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon